Tag: 426.4839

Role of Nrf2/HO-1 signaling pathway in treatment of schizophrenia rats with paliperidone was written by Wang, Li;Zhang, Song;Long, Wei. And the article was included in Zhongguo Laonianxue Zazhi in 2022.COA of Formula: C23H27FN4O3 This article mentions the following:

Objective: To investigate the mechanism of NF-E2-related factor (Nrf)2/heme oxygenase (HO)-1 signaling pathway in the treatment of schizophrenia (SZ) rats with paliperidone. Methods: Fifty SPF SD rats were randomly divided into 5 groups: control group (Control group), SZ group (Model group), risperidone group, low-dose paliperidone group and high-dose paliperidone group. The rat model of SZ development was established by i.p. injection of didroxepine maleate (MK-801, 0.25 mg/kg). Rats in low-dose paliperidone group, high-dose paliperidone group and risperidone group were given paliperidone (0.03 mg/kg, once daily), paliperidone (0.30 mg/kg, once daily) and risperidone (0.10), resp. mg/kg, once a day), and rats in Control group and Model group were given the same amount of normal saline. The open field test box was used to analyze the changes of total distance within 10 min in each group. Morris water maze was used to test the reference memory of rats in each group. Social interaction test box was used to test the social interaction ability of rats in each group. And Western blotting was used to detect the expression levels of Caspase-3, Bax protein, Nrf2 and HO-1 in hippocampus tissues of rats in each group. Results: Compared with the Control group, the total distance of spontaneous activity in the Model group was significantly increased, the escape latency was significantly increased, the frequency of crossing the platform was significantly decreased, and the social interaction time and the percentage of non-aggressive behavior were significantly decreased (P<0.05). Compared with the Model group, the total distance of spontaneous activity in risperidone group, the low-dose paliperidone group and the high-dose paliperidone group were significantly decreased, the escape latency was significantly decreased, the number of platform crossing was significantly increased, the social interaction time and the percentage of non-aggressive behavior were significantly increased (P<0.05). Compared with the Control group, the expression levels of caspas-3 and Bax protein in the Model group were significantly increased, and the expression levels of Nrf2 and HO-1 protein were significantly decreased (P<0.05). Compared with the Model group, the protein expression levels of digested caspase-3 and Bax in the hippocampus of risperidone group, low-dose paliperidone group and high-dose paliperidone group were significantly decreased, and the protein expression levels of Nrf2 and HO-1 were significantly increased (P<0.05). Conclusion: Paliperidone can alleviate abnormal behavior in SZ model rats, and may play a role by regulating Nrf2/HO-1 signaling pathway. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4COA of Formula: C23H27FN4O3).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazoles are aromatic heterocycles containing an N–O bond. The weakness of this bond allows the ring opening of these heterocycles under reductive conditions. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.COA of Formula: C23H27FN4O3

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data) was written by Mauri, Massimo Carlo;Franco, Gemma;Minutillo, Alessandro;Paletta, Silvia;Di Pace, Chiara;Reggiori, Alessandra;Baldelli, Sara;Cattaneo, Dario. And the article was included in Journal of Clinical Psychopharmacology in 2022.Application of 144598-75-4 This article mentions the following:

The aim of the study was a preliminary evaluation of the maintenance of clin. efficacy and tolerability of paliperidone palmitate in patients with schizophrenia during the transition phase from 1-monthly paliperidone palmitate formulation (PP1M) to PP3M, with the evaluation of plasma levels of the drug. A prospective observational study was conducted for 13 mo involving 22 outpatients, aged 18 to 66 years and clin. stabilized. Patients were affected by schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria. For each patient, clin. assessment, safety and tolerability, and drug plasma level determination were performed. Clin. efficacy was assessed by Brief Psychiatric Rating Scale, Pos. and Neg. Symptom Scale, and Hamilton Rating Scale for Depression. During the first 4 mo of the study, once-monthly paliperidone palmitate was administered, and then during the following 9 mo, the 3-monthly formulation was administered. The time course of the Brief Psychiatric Rating Scale total scores showed a statistically significant (P = 0.006) improvement from T0 to T8; Pos. and Neg. Symptom Scale scores showed a similar time course, with a statistically significant (P = 0.0016) reduction of the mean total score; Hamilton Rating Scale for Depression mean scores showed a statistically significant (P = 0.003) reduction with substantial maintenance of clin. stabilization of the patients. Only 1 patient dropped out after the first PP3M injection. Our preliminary data currently confirm the maintenance of clin. stability shifting from PP1M to PP3M. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Application of 144598-75-4).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives. Isoxazole are described as inhibitors of acetylcholinesterase (AChE). Isoxazole ligands bind to and inhibit the Sxc- antiporter. As with isoxazolines, isoxazoles may be cleaved using low-valent titanium obtained from the Kulinkovich reaction.This procedure affords enaminoketones from 2,4-substituted isoxazoles.Application of 144598-75-4

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Effects of genetic polymorphism in CYP2D6, CYP2C19, and the organic cation transporter OCT1 on amitriptyline pharmacokinetics in healthy volunteers and depressive disorder patients was written by Matthaei, Johannes;Brockmoeller, Juergen;Steimer, Werner;Pischa, Konstanze;Leucht, Stefan;Kullmann, Maria;Jensen, Ole;Ouethy, Typhaine;Tzvetkov, Mladen Vassilev;Rafehi, Muhammad. And the article was included in Frontiers in Pharmacology in 2021.Synthetic Route of C23H27FN4O3 This article mentions the following:

The tricyclic antidepressant amitriptyline is frequently prescribed but its use is limited by its narrow therapeutic range and large variation in pharmacokinetics. Apart from interindividual differences in the activity of the metabolizing enzymes cytochrome P 450 (CYP) 2D6 and 2C19, genetic polymorphism of the hepatic influx transporter organic cation transporter 1 (OCT1) could be contributing to interindividual variation in pharmacokinetics. Here, the impact of OCT1 genetic variation on the pharmacokinetics of amitriptyline and its active metabolite nortriptyline was studied in vitro as well as in healthy volunteers and in depressive disorder patients. Amitriptyline and nortriptyline were found to inhibit OCT1 in recombinant cells with IC₅₀ values of 28.6 and 40.4μM. Thirty other antidepressant and neuroleptic drugs were also found to be moderate to strong OCT1 inhibitors with IC₅₀ values in the micromolar range. However, in 35 healthy volunteers, preselected for their OCT1 genotypes, who received a single dose of 25 mg amitriptyline, no significant effects on amitriptyline and nortriptyline pharmacokinetics could be attributed to OCT1 genetic polymorphism. In contrast, the strong impact of the CYP2D6 genotype on amitriptyline and nortriptyline pharmacokinetics and of the CYP2C19 genotype on nortriptyline was confirmed. In addition, acylcarnitine derivatives were measured as endogenous biomarkers for OCT1 activity. The mean plasma concentrations of isobutyrylcarnitine and 2-methylbutyrylcarnitine were higher in participants with two active OCT1 alleles compared to those with zero OCT1 activity, further supporting their role as endogenous in vivo biomarkers for OCT1 activity. A moderate reduction in plasma isobutyrylcarnitine concentrations occurred at the time points at which amitriptyline plasma concentrations were the highest. In a second, independent study sample of 50 patients who underwent amitriptyline therapy of 75 mg twice daily, a significant trend of increasing amitriptyline plasma concentrations with decreasing OCT1 activity was observed (p = 0.018), while nortriptyline plasma concentrations were unaffected by the OCT1 genotype. Altogether, this comprehensive study showed that OCT1 activity does not appear to be a major factor determining amitriptyline and nortriptyline pharmacokinetics and that hepatic uptake occurs mainly through other mechanisms. In the experiment, the researchers used many compounds, for example, 3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4Synthetic Route of C23H27FN4O3).

3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one (cas: 144598-75-4) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Fe(CO)5 efficiently cleaves the N–O bond of fused isoxazolo-1,4-quinones to give the corresponding imines.All the common reducing reagents failed to open the isoxazole ring.Synthetic Route of C23H27FN4O3

Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem